| Revision as of 18:05, 25 February 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to watched fields - updated 'UNII_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacolog← Previous edit |
Latest revision as of 09:21, 13 November 2024 edit undoCbare (talk | contribs)104 editsm Add DrugBank accession |
| (49 intermediate revisions by 33 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
|
| Watchedfields = changed |
|
| Watchedfields = changed |
|
| verifiedrevid = 415664559 |
|
| verifiedrevid = 415900104 |
|
|
| IUPAC_name=3,6,9,12,15,18,21,24,27-nonaoxanonatriacontan-1-ol |
|
| IUPAC_name = |
|
|
| image = Polidocanol skeletal.svg |
|
| image = Polidocanol skeletal.svg |
|
| width = 250 |
|
| width = 250 |
|
|
| alt = |
| ⚫ |
| CAS_number = 9002-92-0 |
|
|
|
|
| ⚫ |
| CAS_supplemental = <br />{{CAS|3055-99-0}} (with nine ] units) |
|
|
|
<!--Clinical data--> |
| ⚫ |
| ATC_prefix = C05 |
|
|
|
| tradename = |
| ⚫ |
| ATC_suffix = BB02 |
|
|
|
| Drugs.com = {{drugs.com|international|polidocanol}} |
| ⚫ |
| ATC_supplemental = |
|
|
| PubChem = 656641 |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
⚫ |
| pregnancy_category = Topical: allowed<br />Injection: contraindication in months 1–3 and after week 36 |
| ⚫ |
| DrugBank = |
|
|
⚫ |
| routes_of_administration = topical, subcutaneous injection |
| ⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
|
⚫ |
| ATC_prefix = C05 |
| ⚫ |
| ChemSpiderID = |
|
|
⚫ |
| ATC_suffix = BB02 |
|
⚫ |
| ATC_supplemental = |
|
|
|
|
⚫ |
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
|
| legal_CA = Rx-only |
|
|
| legal_CA_comment = <ref>{{cite web | title=Health Canada New Drug Authorizations: 2015 Highlights | website=] | date=4 May 2016 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-canada-new-drug-authorizations-2015-highlights.html | access-date=7 April 2024}}</ref> |
|
⚫ |
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
|
⚫ |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
⚫ |
| legal_status = ] (topical), ] (injection) |
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
⚫ |
| bioavailability = |
|
⚫ |
| protein_bound = |
|
⚫ |
| metabolism = |
|
⚫ |
| elimination_half-life = |
|
⚫ |
| excretion = |
|
|
|
|
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
⚫ |
| CAS_number = 9002-92-0 |
|
⚫ |
| CAS_supplemental = <br />{{CAS|3055-99-0}} |
|
|
| PubChem = 656641 |
|
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
⚫ |
| DrugBank = DB06811 |
|
⚫ |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
⚫ |
| ChemSpiderID = 570993 |
|
|
| UNII_Ref = {{fdacite|changed|FDA}} |
|
|
| UNII = 0AWH8BFG9A |
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG = D01993 |
|
| KEGG = D01993 |
|
|
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
| ⚫ |
| C= 30 | H= 62 | O= 10 |
|
|
|
| ChEMBL = 1201751 |
|
| molecular_weight = ~600 g/mol (average) |
|
|
|
|
|
| smiles = |
|
|
|
<!--Chemical data--> |
| ⚫ |
| synonyms = |
|
|
⚫ |
| C=30 | H=62 | O=10 |
|
|
| smiles = CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO |
|
|
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} |
|
|
| StdInChI = 1S/C30H62O10/c1-2-3-4-5-6-7-8-9-10-11-13-32-15-17-34-19-21-36-23-25-38-27-29-40-30-28-39-26-24-37-22-20-35-18-16-33-14-12-31/h31H,2-30H2,1H3 |
|
|
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} |
|
|
| StdInChIKey = ONJQDTZCDSESIW-UHFFFAOYSA-N |
|
⚫ |
| synonyms = |
|
*Polydocanol |
|
*Polydocanol |
|
*Laureth 9 |
|
*Laureth 9 |
| Line 29: |
Line 66: |
|
*Hydroxyl polyethoxy dodecane |
|
*Hydroxyl polyethoxy dodecane |
|
*Oxypolyethoxydodecane |
|
*Oxypolyethoxydodecane |
|
| density = |
|
| density = |
|
|
| melting_notes = |
|
| melting_point = |
|
|
⚫ |
| boiling_point = |
|
| melting_high = |
|
|
| melting_notes = |
|
| solubility = |
| ⚫ |
| boiling_point = |
|
|
| boiling_notes = |
|
|
| solubility = |
|
|
| specific_rotation = |
|
| specific_rotation = |
|
| sec_combustion = |
|
| ⚫ |
| bioavailability = |
|
| ⚫ |
| protein_bound = |
|
| ⚫ |
| metabolism = |
|
| ⚫ |
| elimination_half-life = |
|
| ⚫ |
| excretion = |
|
|
| licence_EU = <!-- EMEA requires brand name --> |
|
|
| licence_US = <!-- FDA may use generic name --> |
|
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| ⚫ |
| pregnancy_category= Topical: allowed<br />Injection: contraindication in months 1–3 and after week 36 |
|
| ⚫ |
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
|
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| ⚫ |
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
|
| ⚫ |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| ⚫ |
| legal_status = ] (topical), ] (injection) |
|
|
| dependency_liability = |
|
| ⚫ |
| routes_of_administration = |
|
|
}} |
|
}} |
|
'''Polidocanol''' is a ] and ] component of ]s and bath additives. It relieves itching caused for example by ] conditions such as ].<ref>{{cite web | url = http://www.netdoctor.co.uk/medicines/100004774.html | title = E45 itch relief cream |
|
'''Polidocanol''' is a ] and ] component of ]s and bath additives. It relieves itching caused by ] and dry skin.<ref>{{cite web | url = http://www.netdoctor.co.uk/medicines/100004774.html | title = E45 itch relief cream | publisher = netdoctor.co.uk | accessdate = 2007-07-12}}</ref> It has also been used to treat ],<ref name="Star_2018">{{cite journal | vauthors = Star P, Connor DE, Parsi K | title = Novel developments in foam sclerotherapy: Focus on Varithena (polidocanol endovenous microfoam) in the management of varicose veins | journal = Phlebology | volume = 33 | issue = 3 | pages = 150–162 | date = April 2018 | pmid = 28166694 | doi = 10.1177/0268355516687864 }}</ref> ]s, and ]s.<ref name="Gao_2018">{{cite journal | vauthors = Gao Z, Zhang Y, Li W, Shi C | title = Effectiveness and safety of polidocanol for the treatment of hemangiomas and vascular malformations: A meta-analysis | journal = Dermatologic Therapy | volume = 31 | issue = 1 | pages = e12568| date = January 2018 | pmid = 29082587 | doi = 10.1111/dth.12568 | doi-access = free }}</ref> It is formed by the ] of ]. |
|
| publisher = netdoctor.co.uk | accessdate = 2007-07-12}}</ref> |
|
|
|
|
|
|
|
==Sclerotherapy== |
|
The substance is also used as a ], an ] injected to treat ], under the trade names '''Asclera''' and '''Aethoxysklerol'''.<ref>, Laurence Z Rosenberg, MD, eMedicine.com</ref> Polidocanol causes ] inside varicose veins, occluding the ] of the vessel, and reducing the appearance of the varicosity. |
|
Polidocanol is also used as a ], an ] injected to treat ], under the trade names '''Asclera''', '''Aethoxysklerol'''<ref>, Laurence Z Rosenberg, MD, eMedicine.com</ref> and '''Varithena'''.<ref>{{cite web|title=Varithena (polidocanol injectable foam) For Intravenous Use. Full Prescribing Information|url=http://varithena.com/Portals/VarithenaPatient/Varithena_Full_Prescribing_Information.pdf|publisher=Biocompatibles, Inc.|accessdate=1 October 2015|archive-url=https://web.archive.org/web/20160804021205/http://varithena.com/Portals/VarithenaPatient/Varithena_Full_Prescribing_Information.pdf|archive-date=4 August 2016|url-status=dead}}</ref> Polidocanol causes ] inside varicose veins, occluding the ] of the vessel, and reducing the appearance of the varicosity. |
|
|
|
|
|
The FDA has approved polidocanol injections for the treatment of small varicose (less than 1 mm in diameter) and reticular veins (1 to 3 mm in diameter). Polidocanol works by damaging the cell lining of blood vessels, causing them to close and eventually be replaced by other types of tissue. <ref>Facts and Companies: </ref><ref>{{cite web |url=http://www.theodora.com/drugs/asclera_polidocanol_bioform_medical.html |title=Asclera Full Prescribing Information in Drug Reference Encyclopedia |format= |work= |accessdate=2010-04-11}}</ref> |
|
The FDA has approved polidocanol injections for the treatment of small varicose (less than 1 mm in diameter) and reticular veins (1 to 3 mm in diameter). Polidocanol works by damaging the cell lining of ], causing them to close and eventually be replaced by other types of tissue.<ref>Facts and Companies: </ref><ref>{{cite web |url=http://www.theodora.com/drugs/asclera_polidocanol_bioform_medical.html |title=Asclera Full Prescribing Information in Drug Reference Encyclopedia |format= |accessdate=2010-04-11}}</ref> Polidocanol in the form of Varithena injected in the greater saphenous vein can cause the eruption of varicose and spider veins throughout the lower leg. This procedure should be done with caution and with the knowledge that the appearance of the leg may be forever compromised. |
|
|
|
|
|
] |
|
] |
|
|
|
|
==References== |
|
==References== |
|
{{reflist}} |
|
{{reflist}} |
| Line 70: |
Line 87: |
|
|
|
|
|
] |
|
] |
|
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
|
|
{{cardiovascular-drug-stub}} |
|
{{cardiovascular-drug-stub}} |
|
{{dermatologic-drug-stub}} |
|
{{dermatologic-drug-stub}} |
|
|
|
|
] |
|
|
] |
|
|
] |
|